This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.
Editas Medicine (EDIT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $21.46, marking a +0.61% move from the previous day.
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
by Zacks Equity Research
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EDIT) Outperforming Other Medical Stocks This Year?
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Editas Medicine (EDIT)
by Kevin Cook
CRISPR gene editing is going to transform the world and this leader just won key patent battles to capitalize
Aerie's Rhopressa Succeeds in Study on Japanese Patients
by Zacks Equity Research
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
by Zacks Equity Research
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Editas Medicine (EDIT) closed at $28, marking a +1.97% move from the previous day.
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Medicine (EDIT) Stock Moves -0.95%: What You Should Know
by Zacks Equity Research
Editas Medicine (EDIT) closed the most recent trading day at $25.98, moving -0.95% from the previous trading session.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Top Performing Active ETFs & Tesla's Best-Case Scenario
by Neena Mishra
Neena Mishra talks with COO of ARK Investment Management, the firm behind most innovative ETFs that have consistently delivered excellent performance.
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
by Zacks Equity Research
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.